As a result of mental or environmental factors, in addition to the purposes of general physical therapy, would also have to assist patients of the causes, psychological guidance, excluding the unfavorable factors. Any hypothalamus, pituitary or ovarian function due to mild disorders, the choice of certain drugs, is expected to induce ovulation in effect.
To ovulation induction therapy, we should first find out the cause of ovulation is not from the hypothalamus - pituitary - ovarian axis which Central or organs before targeted the right. Stunting caused by itself because of ovarian treatment less effective. As a result of mental or environmental factors, in addition to the purposes of general physical therapy, would also have to assist patients of the causes, psychological guidance, excluding the unfavorable factors. Any hypothalamus, pituitary or ovarian function due to mild disorders, the choice of certain drugs, is expected to induce ovulation in effect. Promote ovulation drugs and their role in the target organ for:
① gonadotropin: menopausal gonadotropin - HCG, the role of the ovary is the target organ.
② role of estrogen in the hypothalamus - Ovarian - uterus.
③ Keluomifen role in the hypothalamus.
④ bromocriptine role in the hypothalamus and pituitary.
⑤ gonadotropin-releasing hormone role in the anterior pituitary.
Keluomifen, chlorine Clomiphene and the Shu-fen, for the synthetic system of non-steroidal agents, and chemical structure similar to diethylstilbestrol. Is a kind of strong anti-estrogen effect of the weak and the role of estrogen drugs. Its pharmacological effects of the mechanism is not yet very clear, may be low-dose drug effects in the hypothalamus site, and estrogen receptor competition, lifting the feedback effects of estrogen and stimulate the release of endogenous GnRH, the pituitary gland secretion of FSH and promote LH, Ovulation induction, may also act on the ovary, an increase of follicle gonadotropin response. Keluomifen no direct role in promoting ovulation, nor luteinized, male and the role of anti-male.
Keluomifen the indications are: estrogen in a certain level of functional amenorrhea, Anovulatory dysfunctional uterine bleeding, polycystic ovary syndrome and luteal dysfunction caused by infertility, and so on.
People postmenopausal gonadotropin (HMG) and the villi gonadotropin (HCG) can be combined with ovulation induction. As HMG can cause serious side effects of drug prices and expensive, so the application of HMG-HCG stimulate ovulation should strictly control the following indications: ① primary or secondary low gonadotropin-induced amenorrhea. ② serum gonadotropin normal and the other of ovulation induction is invalid (such as Keluomifen, bromocriptine). ③ adverse reaction to the treatment of ovarian so-called inert. ④ luteal phase defect (LPD). ⑤ cervical factors. ⑥ test-tube babies ovulation induction one of the methods. ⑦ gonadotropin stimulation test.
Gonadotropin the main indications for Anovulatory infertility, luteal dysfunction, and so on. When measured in patients with high levels of serum gonadotropin, ovarian prompted severe stunting, more than the law should not be used to induce ovulation.
If the urinary estrogen total> 150 ng/24 hours or serum estradiol> 1500 pg / ml, should abandon the injection of HCG, so as not to cause ovarian hyperstimulation syndrome. Must point out that the use of ovulation induction dose of HMG and lead to ovarian hyperstimulation syndrome is very close to the limit, the medication required close monitoring, and the need to make more gynaecological examinations to see whether the increased ovarian and tenderness.
HCG injection 10000 u, generally four to five in the future Note 2000 ~ 3000 u to maintain the luteal life. If the HMG-HCG combined during the week failed to conceive, such as the number of consecutive cycles of treatment, and of living arrangements can be injected in large doses a month after the HCG for small change.
To ovulation induction therapy, we should first find out the cause of ovulation is not from the hypothalamus - pituitary - ovarian axis which Central or organs before targeted the right. Stunting caused by itself because of ovarian treatment less effective. As a result of mental or environmental factors, in addition to the purposes of general physical therapy, would also have to assist patients of the causes, psychological guidance, excluding the unfavorable factors. Any hypothalamus, pituitary or ovarian function due to mild disorders, the choice of certain drugs, is expected to induce ovulation in effect. Promote ovulation drugs and their role in the target organ for:
① gonadotropin: menopausal gonadotropin - HCG, the role of the ovary is the target organ.
② role of estrogen in the hypothalamus - Ovarian - uterus.
③ Keluomifen role in the hypothalamus.
④ bromocriptine role in the hypothalamus and pituitary.
⑤ gonadotropin-releasing hormone role in the anterior pituitary.
Keluomifen, chlorine Clomiphene and the Shu-fen, for the synthetic system of non-steroidal agents, and chemical structure similar to diethylstilbestrol. Is a kind of strong anti-estrogen effect of the weak and the role of estrogen drugs. Its pharmacological effects of the mechanism is not yet very clear, may be low-dose drug effects in the hypothalamus site, and estrogen receptor competition, lifting the feedback effects of estrogen and stimulate the release of endogenous GnRH, the pituitary gland secretion of FSH and promote LH, Ovulation induction, may also act on the ovary, an increase of follicle gonadotropin response. Keluomifen no direct role in promoting ovulation, nor luteinized, male and the role of anti-male.
Keluomifen the indications are: estrogen in a certain level of functional amenorrhea, Anovulatory dysfunctional uterine bleeding, polycystic ovary syndrome and luteal dysfunction caused by infertility, and so on.
People postmenopausal gonadotropin (HMG) and the villi gonadotropin (HCG) can be combined with ovulation induction. As HMG can cause serious side effects of drug prices and expensive, so the application of HMG-HCG stimulate ovulation should strictly control the following indications: ① primary or secondary low gonadotropin-induced amenorrhea. ② serum gonadotropin normal and the other of ovulation induction is invalid (such as Keluomifen, bromocriptine). ③ adverse reaction to the treatment of ovarian so-called inert. ④ luteal phase defect (LPD). ⑤ cervical factors. ⑥ test-tube babies ovulation induction one of the methods. ⑦ gonadotropin stimulation test.
Gonadotropin the main indications for Anovulatory infertility, luteal dysfunction, and so on. When measured in patients with high levels of serum gonadotropin, ovarian prompted severe stunting, more than the law should not be used to induce ovulation.
If the urinary estrogen total> 150 ng/24 hours or serum estradiol> 1500 pg / ml, should abandon the injection of HCG, so as not to cause ovarian hyperstimulation syndrome. Must point out that the use of ovulation induction dose of HMG and lead to ovarian hyperstimulation syndrome is very close to the limit, the medication required close monitoring, and the need to make more gynaecological examinations to see whether the increased ovarian and tenderness.
HCG injection 10000 u, generally four to five in the future Note 2000 ~ 3000 u to maintain the luteal life. If the HMG-HCG combined during the week failed to conceive, such as the number of consecutive cycles of treatment, and of living arrangements can be injected in large doses a month after the HCG for small change.
Posts
No comments:
Post a Comment